Narcolepsy

How Narcolepsy Gets Lost in Translation

And what physicians can do by realizing that the words people use to describe their symptoms may not match the disorder’s medical description.

Narcolepsy

Narcolepsy Nightmares Proof-of-Concept Study a Mental ‘Game-Changer’ for Patients

In a small proof-of-concept trial, people with narcolepsy who rescripted their nightmares experienced significant improvements, with half also undergoing a procedure to induce lucid dreaming, which enhanced their ability to recall their revised dreams.

Narcolepsy

A Potential Fix Emerges for Narcolepsy Medication’s Palatability

A study suggests that a way to improve the salty taste of once-nightly sodium oxybate could be found in patients’ refrigerators.

Orexin-2 Receptor Agonist E2086 to Be Tested in Narcolepsy Patients

Jul 8, 2024 | Narcolepsy

Eisai Inc is set to begin enrolling patients for a clinical trial to test the effectiveness and safety of E2086 for narcolepsy type 1.

Narcolepsy Significantly Increases Risk of Cardiovascular Disease

Jun 4, 2024 | Heart, Narcolepsy

Two new studies reveal that narcolepsy is an independent risk factor for cardiovascular disease and adverse cardiac events.

Mazindol Shows Neuroprotective Benefits in Narcolepsy Treatment

May 28, 2024 | Narcolepsy

A preclinical study demonstrates that mazindol mitigates circadian activity disruption in a rat model with narcoleptic-like symptoms.

Avadel to Present New Data on Lumryz for Narcolepsy at SLEEP 2024

May 22, 2024 | Narcolepsy

Avadel will present a series of new analyses highlighting the efficacy, safety, and patient preference for Lumryz, a once-nightly, extended-release formulation of sodium oxybate.

Harmony’s Q1 Report Shows Strong Growth in Sleep/Wake Portfolio

May 1, 2024 | Idiopathic Hypersomnia, Narcolepsy

First-quarter highlights include increased patient uptake of Wakix and steps toward advancing pitolisant for idiopathic hypersomnia.

Jazz to Highlight Narcolepsy and IH Research at AAN 2024

Apr 11, 2024 | Idiopathic Hypersomnia, Narcolepsy

The research includes an oral presentation revealing that individuals with idiopathic hypersomnia experienced higher odds of comorbid conditions, such as cardiovascular disease.

Health Canada Approves Wakix for Pediatric Narcolepsy Patients

Apr 1, 2024 | Narcolepsy

Wakix is the first Health Canada-approved treatment for children 6 years of age and older experiencing excessive daytime sleepiness or cataplexy symptoms associated with narcolepsy.

Survey Sheds Light on Narcolepsy Treatment Challenges

Mar 25, 2024 | Narcolepsy

Axsome Therapeutics’ CRESCENDO survey finds 77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated.

Even Sleep Specialists Can Underestimate Narcolepsy

Mar 5, 2024 | Narcolepsy

Is narcolepsy lost in sleep apnea’s shadow?

Jazz and Avadel Both Secure Wins in Patent Lawsuit Over Narcolepsy Drug

Mar 5, 2024 | Narcolepsy

A jury from the United States District Court for the District of Delaware delivered a mixed verdict in a patent lawsuit between Jazz Pharmaceuticals Inc and Avadel Pharmaceuticals plc concerning Avadel’s narcolepsy medication Lumryz.

Once-Nightly Lumryz Attracts Over 1,200 Narcolepsy Patients Since June Launch

Mar 4, 2024 | Narcolepsy, Pharmaceuticals

Avadel Pharmaceuticals’ CEO says the “meaningful increase” in patients initiating therapy underscores the unmet need for a once-at-bedtime therapy.

FDA Grants Priority Review for Wakix in Pediatric Narcolepsy Treatment

Feb 21, 2024 | Narcolepsy

The FDA has granted priority review to Harmony Biosciences’ supplemental New Drug Application for Wakix for treating excessive daytime sleepiness or cataplexy in children aged 6 and older with narcolepsy.